

ICU Medical to Acquire Pursuit Vascular




One of the world's leading pure-play infusion therapy companies with global operations and a wide-ranging product portfolio including IV systems, solutions and consumables



Developer of ClearGuard® HD antimicrobial barrier caps for hemodialysis catheters, designed to help protect patients from life-threatening infections while reducing healthcare costs

ClearGuard HD Antimicrobial Barrier Caps

- › The first and only device that kills infection-causing bacteria inside a hemodialysis catheter hub to help prevent catheter contamination
- › Reduces central line-associated bloodstream infections by approximately 70% when compared to current products^{1,2}



The ClearGuard HD features a rod that extends into the hemodialysis catheter hub. Both the rod and cap threads are coated with chlorhexidine, a well-known broad-spectrum antimicrobial agent

The antimicrobial coating is dissolved when inserted into the liquid-filled catheter hub, killing harmful microorganisms. The catheter clamp holds the antimicrobial agent inside the hub between treatments

Addressing catheter-line associated bloodstream infections is at the heart of many of ICU Medical's existing IV consumables technologies, and ClearGuard HD provides well-defined synergies.



The addition of Pursuit Vascular's ClearGuard HD will enhance ICU Medical's IV consumables product offering across the company's existing direct and OEM business lines as well as open new customer opportunities globally

¹ Cluster-Randomized Trial of Devices to Prevent Catheter-Related Bloodstream Infection, Steven M. Brunelli, David B. Van Wyck, Levi Njord, Robert J. Ziebol, Laurie E. Lynch and Douglas P. Killion, JASN April 2018, 29 (4) 1336-1343; DOI: <https://doi.org/10.1681/ASN.2017080870>

² Dialysis Catheter-Related Bloodstream Infections: A Cluster-Randomized Trial of the ClearGuard HD Antimicrobial Barrier Cap, Jeffrey L. Hymes, MD, Ann Mooney, MSN, RN, CNN, Carly Van Zandt, MS, Laurie Lynch, PhD, Robert Ziebol, BS, and Douglas Killion, MBA, Am J Kidney Dis. 2017;69(2):220-227